Jakavi (Ruxolitinib)

Ruxolitinib works by selectively blocking the activity of Janus kinase 1 and 2 (JAK1/JAK2). These enzymes are central to cytokine signaling that drives abnormal blood cell production and inflammation. Inhibiting JAK1/JAK2 dampens downstream STAT activation, thereby reducing the proliferation of malignant myeloid cells and alleviating inflammatory symptoms.

The dosage of Jakavi is individualized and determined by the prescribing physician based on the patient’s specific condition, disease severity, and laboratory parameters. Healthcare providers adjust the dose according to response and tolerability, following the approved prescribing information.

Safety data for Jakavi in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare professional.

To order Jakavi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

The primary alternative to Jakavi in myeloproliferative disorders is fedratinib, another JAK2‑selective inhibitor, and hydroxyurea, a cytoreductive agent. Jakavi targets both JAK1 and JAK2, offering broader cytokine modulation, which can translate into greater spleen volume reduction in myelofibrosis. Fedratinib may be preferred when Jakavi is not tolerated, while hydroxyurea remains a first‑line option for polycythemia vera but does not address splenomegaly as effectively.

Jakavi tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Jakavi is taken orally as a tablet, usually with water. It can be taken with or without food, but patients should follow the specific timing instructions provided by their prescriber to maintain consistent drug exposure.

Serious risks include severe infections (such as opportunistic or bacterial infections), hepatic dysfunction indicated by elevated liver enzymes or hepatitis, pulmonary hypertension, and the possible development of secondary malignancies. Patients should promptly report fever, persistent cough, jaundice, shortness of breath, or unexplained weight loss to their healthcare provider.

Jakavi should be avoided in patients with known hypersensitivity to ruxolitinib or any tablet excipients. It is also contraindicated in individuals with active, uncontrolled infections, severe hepatic impairment, or those who are pregnant or breastfeeding without a clear medical justification. Clinicians must evaluate each patient’s medical history before initiating therapy.